Compare Incyte Corporation (INCY) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ProShares Ultra Gold ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while ProShares Ultra Gold ETF trades at $52.3. The key difference: Incyte Corporation is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| INCY | UGL | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $85.62 |
52-Week Low | $81.61 | $34.37 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
UGL is trading at $52.13, up 0.81% on the day, with a bullish technical signal from moving averages but overbought conditions indicated by RSI readings above 76. The stock faces immediate resistance at $52-$53 levels while finding support around $51. Recent gold market strength driven by inflation data and Fed policy expectations provides positive sector momentum.
The stock shows technical strength but requires fundamental validation through earnings reports and financial metrics. Key risks include gold price volatility and Fed policy sensitivity. Investors should monitor upcoming financial disclosures for confirmation of the current technical bullishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
